share_log

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases

生物技術日報:阿卡迪亞抗精神病藥物的大拇指下降,Akebia 未能通過 COVID-19 研究,Kazia 在腦轉移中令人鼓舞的數據
Benzinga Real-time News ·  2022/08/05 11:36
Here's a roundup of top developments in the biotech space over the last 24 hours:
以下是過去24小時生物技術領域的熱門發展綜述:
Stocks In Focus
關注的股票
FDA Signs Off Marker Therapeutics Cell Therapy Study In Lymphoma Setting
FDA批准MARKER治療淋巴瘤的細胞治療研究
The FDA cleared Marker Therapeutics Inc's (NASDAQ:MRKR) Investigational New Drug (IND) application for MT-601 for relapsed/refractory non-Hodgkin lymphoma who have failed or are ineligible to receive anti-CD19 CAR T cell treatment.
FDA批准了標記物治療公司納斯達克代碼:MRKR)MT-601的研究性新藥申請,用於治療未能或沒有資格接受抗CD19CAR T細胞治療的複發性/難治性非霍奇金淋巴瘤。
MT-601 is a multi-tumor-associated antigen (multiTAA)-specific T cell product targeting six antigens.
MT-601是一種針對六種抗原的多腫瘤相關抗原(MultiTAA)特異性T細胞產物。
In addition, the FDA has cleared Marker to initiate its study at a dose level of 200 million cells per infusion versus...
此外,FDA已經批准Marker啟動其研究...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論